Literature DB >> 7370149

Time-course of formation of volatile reductive metabolites of halothane in humans and an animal model.

G K Gourlay, J F Adams, M J Cousins, J H Sharp.   

Abstract

The time-course of the formation of 2-chloro-1,1,1-trifluoroethane (CTF) and 2-chloro-1-1-difluoroethylene (CDF), two recently identified volatile reductive metabolites of halothane, has been studied in four patients receiving 1% halothane with 99% oxygen. The concentrations of CTF and CDF in end-expired breath increased with time and reached a plateau after approximately 60 min from commencing administration. A similar time-course and plateau was seen when Fischer 344 rats were anaesthetized with halothane 1% in oxygen. However, there was an eight-fold and 12-fold increase in CTF and CDF concentrations respectively when halothane 1% was administered under conditions of mild hypoxia (oxygen 14% inspired) to rats pretreated with phenobarbitone (this results in a marked increase in serum alanine aminotransferase (ALT) and necrotic damage in the vicinity of the central veins of the liver). It is suggested that breath concentrations of CDF and CTF provide a sensitive method of monitoring the reductive metabolism of halothane.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7370149

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

1.  Genetics and halothane hepatitis.

Authors:  M J Cousins; G K Gourlay; P Hall; J Adams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-14

2.  Halothane hepatitis in an animal model: time course of hepatic damage.

Authors:  K M Knights; G K Gourlay; P D Hall; J F Adams; M J Cousins
Journal:  Br J Exp Pathol       Date:  1987-10

3.  PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics.

Authors:  David G Levitt
Journal:  BMC Anesthesiol       Date:  2002-08-15       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.